Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin.
Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
Store at 2 to 8 degrees Celsius
Protect from Light
Do not Freeze
Refrigerate
Shelf lifetime is 3 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin.
Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
Store at 2 to 8 degrees Celsius
Protect from Light
Do not Freeze
Refrigerate
Shelf lifetime is 3 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
Store at 2 to 8 degrees Celsius
Protect from Light
Do not Freeze
Refrigerate
Shelf lifetime is 3 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Acromegaly: For the symptomatic control and reduction of growth hormone and IGF-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with Sandostatin. Sandostatin LAR is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,Gastro-entero-pancreatic tumours: For the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - Carcinoid tumours with features of the carcinoid syndrome; - Vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on subcutaneous treatment with Sandostatin.
Sandostatin LAR is not curative in these patients.,Advanced neuroendocrine tumours of the midgut: Treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.
How to take it
This medicine is a pack that contains more than one part.
Part 1: Diluent, not applicable
Clear, colourless to slightly brown solution injection kit 3 ml glass syringe, stainless steel safety needle and vial adapter in a rigid plastic tray.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Part 2: Injection, modified release
White to white with yellowish tint powder in glass vial sealed with rubber stopper and aluminium fliptop seal.
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Storage instructions
Store at 2 to 8 degrees Celsius
Protect from Light
Do not Freeze
Refrigerate
Shelf lifetime is 3 Years.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on October 1, 2023. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
Support for this browser is being discontinued
Support for this browser is being discontinued for this site
Internet Explorer 11 and lower
We currently support Microsoft Edge, Chrome, Firefox and Safari. For more information, please visit the links below:
